A detailed history of China Universal Asset Management Co., Ltd. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 14,572 shares of XENE stock, worth $566,850. This represents 0.06% of its overall portfolio holdings.

Number of Shares
14,572
Previous 8,868 64.32%
Holding current value
$566,850
Previous $345,000 66.09%
% of portfolio
0.06%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$36.12 - $43.96 $206,028 - $250,747
5,704 Added 64.32%
14,572 $573,000
Q2 2024

Jul 19, 2024

SELL
$36.25 - $43.75 $204,885 - $247,275
-5,652 Reduced 38.93%
8,868 $345,000
Q1 2024

Apr 29, 2024

BUY
$42.66 - $50.04 $254,850 - $298,938
5,974 Added 69.9%
14,520 $625,000
Q4 2023

May 21, 2024

SELL
$28.7 - $46.46 $171,453 - $277,552
-5,974 Reduced 41.14%
8,546 $393,000
Q4 2023

Jan 23, 2024

BUY
$28.7 - $46.46 $197,886 - $320,341
6,895 Added 417.63%
8,546 $394,000
Q3 2023

May 21, 2024

BUY
$34.16 - $39.73 $27,942 - $32,499
818 Added 98.2%
1,651 $56,000
Q3 2023

Oct 30, 2023

BUY
$34.16 - $39.73 $27,942 - $32,499
818 Added 98.2%
1,651 $56,000
Q2 2023

May 21, 2024

SELL
$34.84 - $43.54 $522 - $653
-15 Reduced 1.77%
833 $32,000
Q2 2023

Jul 27, 2023

SELL
$34.84 - $43.54 $522 - $653
-15 Reduced 1.77%
833 $32,000
Q1 2023

May 21, 2024

BUY
$33.46 - $40.35 $7,126 - $8,594
213 Added 33.54%
848 $30,000
Q1 2023

Apr 27, 2023

BUY
$33.46 - $40.35 $7,126 - $8,594
213 Added 33.54%
848 $30,000
Q4 2022

May 21, 2024

SELL
$33.06 - $39.43 $459,038 - $547,485
-13,885 Reduced 95.63%
635 $25,000
Q4 2022

Jan 31, 2023

BUY
$33.06 - $39.43 $1,719 - $2,050
52 Added 8.92%
635 $25,000
Q3 2022

Oct 21, 2022

BUY
$30.79 - $39.82 $17,950 - $23,215
583 New
583 $21,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.42B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.